Trends over time in pap and pap-HPV cotesting for cervical cancer screening

Kathy Mac Laughlin, Robert M Jacobson, Carmen Radecki Breitkopf, Patrick M. Wilson, Debra J. Jacobson, Chun Fan, Jennifer St. Sauver, Lila J Rutten

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: In 2012, updated cervical cancer screening recommendations were released with consensus on Papanicolaou (Pap) testing every 3 years for women age 21-65 years or Pap-human papillomavirus (HPV) cotesting at 5-year intervals for women age 30-65 years. Primary study aims: Assess current use of Pap-HPV cotesting and describe local population trends over time in Pap and Pap-HPV cotesting. Secondary aim: Assess sociodemographic factors correlating with screening. Methods: We assessed Rochester Epidemiology Project data for Pap and Pap-HPV cotesting among women age 16 years and older living in Olmsted County, Minnesota, yearly from 2005 (study population n = 47,203) through 2016 (study population n = 49,510). We calculated 3-year (Pap) and 5-year (Pap-HPV) moving prevalence rates of screening as proportion of eligible population. Multivariable logistic regression was used to assess factors potentially associated with screening. Results: In 2016, 64.6% of 27,418 eligible 30-to 65-year-old women were up to date with cervical cancer screening; 60.8% had received Pap-HPV cotest screening. Significant declines in Pap completion rates over time were observed in all age groups, including an unexpected decline in 21-to 29-year-old women. Coincident with decreasing Pap screening rates, Pap-HPV cotesting significantly increased among women age 30-65 years, from 10.0% in 2007 to 60.8% in 2016. Conclusions: This suggests increasing adoption of 2012 screening recommendations in the 30-to 65-year-old population. However, decline in Pap screening among 21-to 29-year-old women is concerning. Disparities by race, ethnicity, smoking status, and comorbidity level were observed. Results suggest need for multilevel patient and clinician interventions to increase cervical cancer screening adherence.

Original languageEnglish (US)
Pages (from-to)244-249
Number of pages6
JournalJournal of Women's Health
Volume28
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Early Detection of Cancer
Uterine Cervical Neoplasms
Population
Comorbidity
Epidemiology
Age Groups
Logistic Models
Smoking

Keywords

  • adolescent health
  • gynecologic cancer
  • health disparities
  • sexually transmitted infections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Trends over time in pap and pap-HPV cotesting for cervical cancer screening. / Mac Laughlin, Kathy; Jacobson, Robert M; Radecki Breitkopf, Carmen; Wilson, Patrick M.; Jacobson, Debra J.; Fan, Chun; St. Sauver, Jennifer; Rutten, Lila J.

In: Journal of Women's Health, Vol. 28, No. 2, 01.02.2019, p. 244-249.

Research output: Contribution to journalArticle

@article{319f6d0f1b124d0db2cef2de8a61c2fb,
title = "Trends over time in pap and pap-HPV cotesting for cervical cancer screening",
abstract = "Background: In 2012, updated cervical cancer screening recommendations were released with consensus on Papanicolaou (Pap) testing every 3 years for women age 21-65 years or Pap-human papillomavirus (HPV) cotesting at 5-year intervals for women age 30-65 years. Primary study aims: Assess current use of Pap-HPV cotesting and describe local population trends over time in Pap and Pap-HPV cotesting. Secondary aim: Assess sociodemographic factors correlating with screening. Methods: We assessed Rochester Epidemiology Project data for Pap and Pap-HPV cotesting among women age 16 years and older living in Olmsted County, Minnesota, yearly from 2005 (study population n = 47,203) through 2016 (study population n = 49,510). We calculated 3-year (Pap) and 5-year (Pap-HPV) moving prevalence rates of screening as proportion of eligible population. Multivariable logistic regression was used to assess factors potentially associated with screening. Results: In 2016, 64.6{\%} of 27,418 eligible 30-to 65-year-old women were up to date with cervical cancer screening; 60.8{\%} had received Pap-HPV cotest screening. Significant declines in Pap completion rates over time were observed in all age groups, including an unexpected decline in 21-to 29-year-old women. Coincident with decreasing Pap screening rates, Pap-HPV cotesting significantly increased among women age 30-65 years, from 10.0{\%} in 2007 to 60.8{\%} in 2016. Conclusions: This suggests increasing adoption of 2012 screening recommendations in the 30-to 65-year-old population. However, decline in Pap screening among 21-to 29-year-old women is concerning. Disparities by race, ethnicity, smoking status, and comorbidity level were observed. Results suggest need for multilevel patient and clinician interventions to increase cervical cancer screening adherence.",
keywords = "adolescent health, gynecologic cancer, health disparities, sexually transmitted infections",
author = "{Mac Laughlin}, Kathy and Jacobson, {Robert M} and {Radecki Breitkopf}, Carmen and Wilson, {Patrick M.} and Jacobson, {Debra J.} and Chun Fan and {St. Sauver}, Jennifer and Rutten, {Lila J}",
year = "2019",
month = "2",
day = "1",
doi = "10.1089/jwh.2018.7380",
language = "English (US)",
volume = "28",
pages = "244--249",
journal = "Journal of women's health (2002)",
issn = "1540-9996",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Trends over time in pap and pap-HPV cotesting for cervical cancer screening

AU - Mac Laughlin, Kathy

AU - Jacobson, Robert M

AU - Radecki Breitkopf, Carmen

AU - Wilson, Patrick M.

AU - Jacobson, Debra J.

AU - Fan, Chun

AU - St. Sauver, Jennifer

AU - Rutten, Lila J

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Background: In 2012, updated cervical cancer screening recommendations were released with consensus on Papanicolaou (Pap) testing every 3 years for women age 21-65 years or Pap-human papillomavirus (HPV) cotesting at 5-year intervals for women age 30-65 years. Primary study aims: Assess current use of Pap-HPV cotesting and describe local population trends over time in Pap and Pap-HPV cotesting. Secondary aim: Assess sociodemographic factors correlating with screening. Methods: We assessed Rochester Epidemiology Project data for Pap and Pap-HPV cotesting among women age 16 years and older living in Olmsted County, Minnesota, yearly from 2005 (study population n = 47,203) through 2016 (study population n = 49,510). We calculated 3-year (Pap) and 5-year (Pap-HPV) moving prevalence rates of screening as proportion of eligible population. Multivariable logistic regression was used to assess factors potentially associated with screening. Results: In 2016, 64.6% of 27,418 eligible 30-to 65-year-old women were up to date with cervical cancer screening; 60.8% had received Pap-HPV cotest screening. Significant declines in Pap completion rates over time were observed in all age groups, including an unexpected decline in 21-to 29-year-old women. Coincident with decreasing Pap screening rates, Pap-HPV cotesting significantly increased among women age 30-65 years, from 10.0% in 2007 to 60.8% in 2016. Conclusions: This suggests increasing adoption of 2012 screening recommendations in the 30-to 65-year-old population. However, decline in Pap screening among 21-to 29-year-old women is concerning. Disparities by race, ethnicity, smoking status, and comorbidity level were observed. Results suggest need for multilevel patient and clinician interventions to increase cervical cancer screening adherence.

AB - Background: In 2012, updated cervical cancer screening recommendations were released with consensus on Papanicolaou (Pap) testing every 3 years for women age 21-65 years or Pap-human papillomavirus (HPV) cotesting at 5-year intervals for women age 30-65 years. Primary study aims: Assess current use of Pap-HPV cotesting and describe local population trends over time in Pap and Pap-HPV cotesting. Secondary aim: Assess sociodemographic factors correlating with screening. Methods: We assessed Rochester Epidemiology Project data for Pap and Pap-HPV cotesting among women age 16 years and older living in Olmsted County, Minnesota, yearly from 2005 (study population n = 47,203) through 2016 (study population n = 49,510). We calculated 3-year (Pap) and 5-year (Pap-HPV) moving prevalence rates of screening as proportion of eligible population. Multivariable logistic regression was used to assess factors potentially associated with screening. Results: In 2016, 64.6% of 27,418 eligible 30-to 65-year-old women were up to date with cervical cancer screening; 60.8% had received Pap-HPV cotest screening. Significant declines in Pap completion rates over time were observed in all age groups, including an unexpected decline in 21-to 29-year-old women. Coincident with decreasing Pap screening rates, Pap-HPV cotesting significantly increased among women age 30-65 years, from 10.0% in 2007 to 60.8% in 2016. Conclusions: This suggests increasing adoption of 2012 screening recommendations in the 30-to 65-year-old population. However, decline in Pap screening among 21-to 29-year-old women is concerning. Disparities by race, ethnicity, smoking status, and comorbidity level were observed. Results suggest need for multilevel patient and clinician interventions to increase cervical cancer screening adherence.

KW - adolescent health

KW - gynecologic cancer

KW - health disparities

KW - sexually transmitted infections

UR - http://www.scopus.com/inward/record.url?scp=85061605885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061605885&partnerID=8YFLogxK

U2 - 10.1089/jwh.2018.7380

DO - 10.1089/jwh.2018.7380

M3 - Article

C2 - 30614380

AN - SCOPUS:85061605885

VL - 28

SP - 244

EP - 249

JO - Journal of women's health (2002)

JF - Journal of women's health (2002)

SN - 1540-9996

IS - 2

ER -